Published in J Immunol on September 24, 2014
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer (2016) 0.92
Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. JAAD Case Rep (2016) 0.78
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight (2017) 0.78
Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine (2017) 0.75
Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells. Int J Mol Med (2017) 0.75
Strategies for designing synthetic immune agonists. Immunology (2016) 0.75
Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma. Onco Targets Ther (2017) 0.75
Roles for Innate Immunity in Combination Immunotherapies. Cancer Res (2017) 0.75
Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol (2017) 0.75
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Innate immunity to virus infection. Immunol Rev (2009) 7.04
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
The CD8+ dendritic cell subset. Immunol Rev (2010) 3.32
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer (2010) 2.03
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol (2002) 1.66
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66
Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol (2012) 1.62
TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol (2007) 1.60
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia (2009) 1.49
Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS (2001) 1.46
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene (2013) 1.40
Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol (2001) 1.31
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol (2010) 1.19
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol (2009) 1.17
CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis (2012) 1.11
Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol (2014) 1.10
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity. J Immunol (2012) 1.06
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
Alterations of surface properties by macrophage activation: expression of receptors for Fc and mannose-terminal glycoproteins and differentiation antigens. Contemp Top Immunobiol (1984) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine (2011) 1.03
Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer (2013) 1.00
M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res (2012) 0.98
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother (2011) 0.96
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol (2006) 0.95
Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo) (2009) 0.94
Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol (2013) 0.91
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res (2008) 0.91
The role of topical immune response modifiers in skin cancer. Drugs (2006) 0.90
PD-1-targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol (2012) 0.88
Uveal melanoma: the inflammatory microenvironment. J Innate Immun (2012) 0.87
Innate immunity. Curr Opin Immunol (2013) 0.86
Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol (2006) 0.79